Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
BioInfusion and other store brands provided a lot of life to Walgreens’ Q4 earnings, it was announced this week by the retailer.
Private label sales shot up by 15% compared to last year, the company said. The figure includes both products sold and marketed under the Walgreens label and “captive” brands like bioInfusion, which carry no evidence of the retailer’s affiliation.
While the company did not break out private label sales in dollars, Walgreens was on track with analysts’ predictions of 45 cents per earnings share.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in